

FORM PTO-1449
(REV. 7-85)U.S. DEPT. OF COMMERCE
PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOC. NO.
G-33302P1
APPLICATION NO.
10/031,874
APPLICANT
NANDI ET AL.
FILING DATE
JULY 31, 2003

Sheet 1 of 1

Group 1623

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA	6,399,637	6/4/02	Filic et al.			
	AB	6,589,556	7/8/03	Cherukuri			
	AC	3,878,217	4/16/75	Carr et al.			
	AD	4,254,129	3/3/81	Carr et al.			
	AE	4,285,957	8/25/81	Carr et al.			
	AF	4,929,605	5/29/90	Domet et al.			
	AG	4,996,061	2/26/91	Webb et al.			
	AH	6,576,836	6/10/03	Webb et al.			
	AI						
	AJ						
	AK						
	AL						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AM						<input type="checkbox"/>	<input type="checkbox"/>
	AN						<input type="checkbox"/>	<input type="checkbox"/>
	AO						<input type="checkbox"/>	<input type="checkbox"/>
	AP						<input type="checkbox"/>	<input type="checkbox"/>
	AQ						<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	AR	
	AS	
	AT	

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

CASE G-33302P1

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10	
<u>EV 457867826 US</u> Express Mail Label Number	<u>June 24, 2004</u> Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF
NANDI ET AL.

EXAMINER: MICHAEL C. HENRY
ART UNIT: 1623

APPLICATION NO: 10/631,874

FILED: JULY 31, 2003

FOR: FEXOFEDADINE COMPOSITION AND PROCESS FOR
PREPARING

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

FEE LETTER FOR SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:


Please charge Deposit Account No. 19-0134 in the name of Novartis in the amount of \$180 for payment of the fee pursuant to 37 CFR §1.17(p) for the submission of an Information Disclosure Statement under 37 CFR §1.97(c).

An additional copy of this paper is here enclosed. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 19-0134 in the name of Novartis.

Respectfully submitted,

Novartis
Corporate Intellectual Property
One Health Plaza, Building 430
East Hanover, NJ 07936-1080

Date: June 24, 2004


John D. Thallemer
Attorney for Applicants
Reg. No. 34,940
(862) 778-7945